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REVIEW
Abstract: About 5 million Americans suffer from heart failure. Given the correlation of
heart failure with age and the rising life expectancy, the prevalence of heart failure continues
to increase in the general population. Sympathetic stimulation intensifies with progressive
heart failure. The rationale to use β-blockers in individuals with impaired myocardial function
is based on experimental evidence supporting the notion that prolonged α- and β-adrenergic
stimulation leads to worsening heart failure. Until recently, safety concerns have precluded
the use of β-blockers in patients with diabetes and heart failure. However, several large,
randomized, placebo-controlled clinical trials such as Metoprolol Randomized Intervention
Trial in Congestive Heart Failure (MERIT-HF) have shown that β-blockers can be safely
used in patients with diabetes and heart failure. Moreover, β-blockers significantly improved
morbidity and mortality in this population. Based on this evidence, it is now recommended to
add β-blockers such as metoprolol CR/XL with an escalating dosage regimen to the treatment
of patients with symptomatic heart failure who already are receiving a stable medical regimen
including angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, diuretics,
vasodilators, or digitalis.
Keywords: metoprolol, heart failure, diabetes mellitus, β-adrenergic blocking agents, MERIT-
HF
Introduction
The first β-adrenergic receptor antagonist for medical purposes was introduced by
Powell and Slater (1958) (dichloroisoproterenol), but its use was limited by a partial
agonist activity (Hoffman and Lefkowitz 1996). The synthesis of pronethalol (Black
and Stephenson 1962) was soon followed by the chemically similar propranolol, and
the latter remains the prototype to which other β-adrenergic receptor antagonists are
compared. Propranolol has equal affinity for β1 and β2 receptors; this caused
bronchospasm and peripheral arterial vasoconstriction in susceptible individuals.
The molecule was subsequently modified to achieve β1 selectivity. This lead to the
discovery of many new compounds (Cruickshank 1980; Benfield et al 1986; Reynolds
et al 1986). Among them was metoprolol tartrate (Waagstein et al 1975), with a half-
life of 3 to 4 hours. In the early 1990s, metoprolol succinate was developed, which is
less water-soluble than the tartrate salt and provides a longer half-life (Polsker and
Clissold 1992).
The metoprolol controlled/extended release (CR/XL) formulation utilizes the
succinate salt of the drug. Each metoprolol CR/XL tablet comprises individual
spherical pellets of the active drug coated with a non-proteolytic polymeric membrane,
mainly ethylcellulose. A 100 mg CR/XL tablet contains 95 mg of metoprolol succinate
and is considered to have equivalent activity to 100 mg metoprolol tartrate. After
The use of metoprolol CR/XL in the treatment
of patients with diabetes and chronic heart
failure
Ovidio De Freitas
Oliver Lenz
Alessia Fornoni
Barry J Materson
Division of Nephrology and
Hypertension, Department of
Medicine, Miller School of Medicine,
University of Miami, Miami, Florida,
USA
Correspondence: Barry J Materson
Division of Nephrology and
Hypertension, Department of Medicine,
Miller School of Medicine, University of
Miami OPPRP (D-54), PO Box 016960,
Miami, FL 33131, USA
Tel +1 305 243 7221
Fax +1 305 243 9902
Email bmaterson@med.miami.eduVascular Health and Risk Management 2006:2(2) 140
De Freitas et al
ingestion, the tablet disintegrates into individual pellets and
each pellet acts as a diffusion cell releasing the drug at a
relatively constant rate over a period of approximately 20
hours (Amitabh and Markham 2000). In this article, we will
review and analyze the available studies on the use of
metoprolol CR/XL in the treatment of patients with diabetes
mellitus and chronic heart failure (CHF).
Diabetes and heart failure
National hospital surveys estimate that about 5 million
Americans have heart failure (AHA 2004). The prevalence
of heart failure and left ventricular dysfunction increases
steeply with age. As an example, the Framingham Heart
Study found a prevalence in men of 8 per 1000 at age 50 to
59 years, increasing to 66 per 1000 at ages 80 to 89 years;
similar values (8 and 79 per 1000) were noted in women
(Ho et al 1993). The prevalence in African-Americans is
reported to be 25% higher than in Caucasians. Diabetes was
found to be an independent predictor of heart failure in this
cohort. The risk of heart failure was increased 2–4-fold in
men and 5-fold in women with diabetes when compared
with those without diabetes, after adjusting for the presence
of hypertension and coronary artery disease (Kannel et al
1974; Marwick 2006). Population-based studies showed
that, depending on the sensitivity of the screening method,
30% to 60% of subjects with well-controlled type 2 diabetes
had diastolic dysfunction (Bell 2003).
The pathogenesis of heart failure in patients with diabetes
is multifaceted. There is a direct relationship between
pathologic changes seen in the myocardium of patients with
diabetes, such as myocardial fibrosis, matrix expansion, and
thickening of the capillary basement membranes, as well as
functional changes in the heart (Fischer et al 1979; van
Hoeven and Factor 1990). These abnormalities, termed
diabetic cardiomyopathy, lead to both systolic and diastolic
dysfunction (Arvan et al 1988; Stone et al 1989). In addition,
the prevalence of coronary artery disease is particularly high
among patients with diabetes, and 75% of type 2 diabetic
subjects have hypertension, 71% left ventricular
hypertrophy, and 52% have diastolic dysfunction. All are
known risk factors for the development of CHF (Kannel
and McGee 1979; Almdal et al 2004). Other pathologic
aspects associated with heart failure and diabetes mellitus
include autonomic neuropathy, impaired metabolic demands
due to abnormal epicardial vessel tone, and microvascular
dysfunction (due in part to down regulation of the expression
of vascular endothelial growth factor), and the decrease in
insulin availability or responsiveness that can impair energy-
independent transport of glucose (Zarich and Nesto 1989;
Sun et al 1994; Rossen 1996; Yoon et al 2005). For a detailed
discussion of the pathogenetic mechanisms underlying
diabetic cardiomyopathy we refer the reader to a recently
published review (Fang et al 2004). The importance of
glycemic control is illustrated by the finding that every 1%
increase in glycosylated hemoglobin (A1c) is associated
with an 8% increased risk of heart failure (Iribarren et al
2001).
Treatment of chronic heart failure
The American Heart Association (AHA) recently published
their updated 2005 guideline for the diagnosis and
management of CHF in the adult (Hunt 2005). These
guidelines recommend the use of both angiotensin-
converting enzyme (ACE) inhibitors and β-blockers to
prevent the progression of CHF. Three β-blockers have been
shown to reduce the risk of death in patients with CHF:
bisoprolol (Dargie and Lechat 1999), metoprolol
(Hjalmarson et al 2000), and carvedilol (Dargie 2001; Packer
et al 2001). The rationale to use β-blockers is based on the
markedly increased sympathetic activity in patients with
CHF. The positive inotropic effect of this sympathetic
activation is far outweighed by its adverse effects, which
include myocardial ischemia, arrhythmogenicitiy, sodium
retention, hypokalemia, and myocardial cell death and
apoptosis (Gebhardt and Wisenberg 1985; Sundberg and
Gordin 1986; Molina-Viamonte et al 1991; Kaumann and
Sanders 1993; Knowlton et al 1993; Communal et al 1998).
In the following, we will briefly review the most relevant
and most recent studies that support the use of metoprolol
for the treatment of heart failure.
Metoprolol Randomized Intervention
Trial in Congestive Heart Failure
(MERIT-HF)
After the conclusion of the MERIT-HF pilot study
(Goldstein et al 1999), which established safety and efficacy
using intermediate endpoints, MERIT-HF was launched.
MERIT-HF is a randomized double-blind placebo-controlled
trial with a single blind, 2-week placebo run-in period
(Hjalmarson et al 2000). A total of 3991 patients with
symptomatic CHF and decreased left ventricular ejection
fraction who were stabilized with standard treatment, were
randomized to receive placebo (2001 patients) or metoprolol
CR/XL (1990 patients). The first 3 predefined outcomes inVascular Health and Risk Management 2006:2(2) 141
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MERIT-HF were all-cause mortality, the combined end point
of all-cause mortality plus all-cause hospitalization (time
to event analysis), and all-cause mortality or hospitalizations
due to worsening heart failure (time to event analysis).
Additional predefined endpoints were the total number of
hospitalizations due to cardiovascular causes and to
worsening heart failure, withdrawal of study drug for any
cause and worsening heart failure. The major inclusion
criteria were symptomatic heart failure for at least 3 months,
corresponding to New York Heart Association (NYHA) class
II to IV, and a left ventricular ejection fraction of 40% or
less in men and women aged 40 to 80 years. Patients had to
be receiving optimal treatment (defined as any combination
of diuretics and an ACE inhibitor) for at least 2 weeks prior
to randomization. Digitals preparations were allowed but
not required. If an ACE inhibitor was not tolerated,
hydralazine, long-acting nitrates, or an angiotensin receptor
blocker (ARB) could be used. The starting dosage of
metoprolol CR/XL was 25 mg daily in NYHA class II and
12.5 mg for patients with NYHA functional class III or IV.
The goal was to double the dose after each 2-week period
to reach the target of 200 mg per day of metoprolol CR/XL
or placebo.
The trial was stopped early because the second interim
analysis showed a significant 34% reduction in total
mortality in the metoprolol CR/XL group compared with
the placebo group. The second primary endpoint, a
composite of all-caused mortality or all-caused
hospitalizations, was reduced by 19% (95% confidence
interval [CI], 10%–27%). Analysis of secondary endpoints
showed that total mortality or hospitalization for worsening
heart failure was reduced by 31% (95% CI, 20%–40%),
death or heart transplantation by 32% (95% CI, 16%–45%),
and cardiac death or nonfatal acute myocardial infarction
by 39% (95% CI, 25%–51%). Total mortality or
hospitalization or emergency department visit due to
worsening heart failure was lowered by 32% (95% CI, 21%–
41%). Compared with placebo, metoprolol CR/XL reduced
the number of patients with any hospitalization (p=0.04),
the total number of hospitalizations (p=0.05), and the total
numbers of days in the hospital (p=0.04), due to all causes.
Improvement in NYHA functional class was recorded in
28.6% versus 25.8% in the metoprolol CR/XL and placebo
groups, respectively. Adverse events necessitating
withdrawal of study drug were similar in both groups.
A subgroup analysis evaluated outcomes in the 985
patients with diabetes that were included in this study
(Deedwania et al 2005). Those in the placebo arm
experienced an 8% increase in mortality and markedly
increased hospitalization rates when compared with patients
without diabetes (48% risk increase for hospitalizations due
to cardiovascular causes; 76% risk increase for
hospitalizations due to heart failure). Hospitalization rates
were significantly lower in patients with diabetes who
received metoprolol (risk reduction [RR] for all-cause
hospitalization: 37%, p=0.0026). This risk reduction was
greater in those with severe heart failure (RR 53%,
p=0.0087). Given the small sample size, a mortality benefit
could not be shown (RR 18%, p>0.2).
Carvedilol or Metoprolol European Trial
(COMET)
The COMET trial is a multicenter, randomized, double-
blind, parallel-group trial to compare the effect on mortality
and morbidity of carvedilol and metoprolol in patients with
CHF (Poole-Wilson et al 2003). 3029 patients were
randomized to receive either 3.125 mg carvedilol twice daily
or 5 mg metoprolol tartrate twice daily. Eligible patients were
men or women with symptomatic CHF (NYHA II–IV) who
had at least one cardiovascular admission during the
previous 2 years and who received stable heart failure
treatment with ACE inhibitors and diuretics for at least 4
weeks. Digitals, angiotensin II inhibitors, or vasodilators
could be used alternatively. Left ventricular ejection fraction
had to be 35% or lower at study entry. The dosage of
medication was titrated every 2 weeks up to the target doses
(carvedilol 25 mg twice daily or metoprolol 50 mg twice
daily). The primary endpoints were all-cause mortality,
cardiovascular deaths, non-cardiovascular deaths, and all-
cause mortality or all-cause hospital admission. Overall, this
study favored carvedilol over metoprolol in terms of all-
cause and cardiovascular mortality, as well as serious and
non-serious adverse events. However, the mortality
difference between the metoprolol or carvedilol group in
the subgroup of patients with diabetes, which comprised
24% of the patients in either arm, did not reach statistical
significance (hazard ratio [HR] 0.85, 95% CI, 0.69–1.06).
Comments and conclusions
Many physicians are still hesitant to prescribe β-blockers
to patients with diabetes and CHF. This may be in part due
to concerns about tolerability and safety as well as to the
paucity of data in regard to efficacy on mortality and
hospitalizations. Based on recent clinical data, β-blockers
clearly confer a benefit in patients with diabetes and heartVascular Health and Risk Management 2006:2(2) 142
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failure, prompting the AHA to endorse this therapy in its
recent practice guidelines (Hunt 2005). In fact, a recent meta-
analysis of the survival benefit of β-blockers in the Cardiac
Insufficiency Bisoprolol Study II (CIBIS II), MERIT-HF,
and the Carvedilol Prospective Randomized Cumulative
Survival Study (COPERNICUS) showed a 25% survival
benefit for patients with diabetes and CHF who received a
β-blocker (Deedwania et al 2005). This is in line with prior
analyses that studied sub-populations of patients with heart
failure (race, gender, and diabetes) using ACE inhibitors
and β-blockers (Shekelle et al 2003). In a meta-analysis
including CIBIS-II, Beta-Blocker Evaluation in Survival
Trial (BEST), Australia–New Zealand-Carvedilol,
Carvedilol US Trials (COPERNICUS), and MERIT-HF, the
benefit derived from β-blocker therapy appeared to be
smaller in those with diabetes when compared with subjects
without diabetes who had CHF (Haas et al 2003). A more
recent meta-analysis of seven randomized-controlled trials
with carvedilol did not find a significant difference in the
relative RR for mortality in subjects with or without diabetes
(28% vs 37%) or the number needed to treat, which was 23
for nondiabetic patients, and 25 for the diabetic group (Bell
et al 2006). However, given the higher absolute risk for death
in patients with diabetes (Deedwania et al 2005), a similar
relative RR will still result in more deaths in the diabetic
than in the nondiabetic group.
The discussion whether the choice of β-blocker will
result in significantly different outcomes is still ongoing.
Two major criticisms have been brought forward in regard
to COMET. The achieved dose of metoprolol was only 78 mg
daily, versus 155 mg in MERIT-HF. In addition, patients
randomized to carvedilol achieved a 1.8 mm Hg greater
reduction in systolic blood pressure at 4 months. These
differences make it more difficult to put the COMET results
into perspective. It should be noted, however, that the
achieved reduction in heart rate in COMET participants was
equivalent in both the metoprolol and carvedilol group,
suggesting a comparable degree of β blockade. In addition,
a post-hoc analysis of the MERIT-HF study according to
achieved dose (≤100 mg vs >100 mg) did not show a
significant mortality difference (Wikstrand et al 2002). In
the post study phase of the COMET trial, which allowed
crossover, mortality was lower in those patients who
switched therapy from metoprolol to carvedilol than in those
who switched from carvedilol to metoprolol or those who
stayed on metoprolol (Di Lenarda et al 2005). In addition, a
randomized controlled trial in patients with diabetes and
hypertension treated with either carvedilol or metoprolol
showed that metabolic control was significantly better in
those receiving carvedilol (Bakris et al 2004).
There is a special concern regarding β blockade in
patients with diabetes mellitus. Theoretically, the activation
of β-adrenergic receptors increases glucose production by
stimulating both glucogenolysis and gluconeogenesis,
protecting against the development of hypoglycemia. It has
been shown that nonselective β-blockers could retard
recovery from insulin-induced hypoglycemia (Antonis et
al 1967; Reveno and Rosenbaum 1968), and the reactions
could be severe, presumably due to diminished or absent
early warning signs (Hirsch et al 1991). However, others
found that the effects on glucose metabolism are less
prominent with β1-selective preparations, making it difficult
to demonstrate an increased risk of serious hypoglycemia
among diabetic populations (Deacon and Barnett 1976;
Shorr et al 1997).
Additional prospective data are needed to decide whether
selective β1 blockade is equivalent to combined β1, β2, and
α1 blockade. However, based on the evidence from large
randomized controlled clinical trials showing a significant
survival benefit, the use of β blockers in patients with
diabetes and CHF should be encouraged. β-blockers should
be introduced at a low starting dose, which is 12.5 mg daily
for metoprolol CR/XL, in symptomatic patients who already
are receiving a stable medical regimen including ACE
inhibitors or ARBs and diuretics, or an alternative regimen
with vasodilators if neither ACE inhibitors nor ARBs are
tolerated. The β-blocker dose should be maximized as
tolerated, and a reasonable target dose for metoprolol
appears to be 150–200 mg daily based on the MERIT-HF
data. Used in this fashion, extended-release preparations of
metoprolol can be safely used in patients with diabetes and
heart failure to reduce morbidity and mortality.
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